Cambridge, United States
Transition Bio, Inc., founded in 2020, is a cutting-edge player in the Biotechnology and Health Care sectors, headquartered in the United States. The company is pioneering the only end-to-end condensate drug discovery platform, branded as Condensomics, that leverages advanced biophysics and artificial intelligence technologies for the analysis of biomolecular condensates.
By utilizing droplet microfluidic approaches and cellular platforms, Transition Bio achieves unprecedented precision in characterizing and mapping condensates. This innovative approach feeds proprietary datasets into algorithms crucial for target discovery, validation, and drug design, providing a robust edge in the competitive drug discovery landscape.
The company's promising trajectory is underscored by a substantial $50.00M Series A investment closed on 02 June 2022, featuring notable investors such as Magnetic Ventures, LifeForce Capital, Northpond Ventures, Taiho Ventures, and Bristol-Myers Squibb.
